Therapeutics Company Receives Buy Rating From Major Investment Firm

BriaCell Therapeutics Corp. (Nasdaq: BCTX), a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care, has recently reported significant positive clinical data for its lead product candidate, Bria-IMT™. This update has earned the company a reiterated "Buy" rating from HC Wainwright & Co., with an impressive price target of $18, far above the current trading price of approximately $1.40. This article delves into the details of BriaCell's recent achievements and the implications for its future in the oncology field. $BriaCell Therapeutics(BCTX.US)$